{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:57:35Z","timestamp":1773043055528,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jns.2013.06.018","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T22:56:51Z","timestamp":1376089011000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Myasthenia gravis: New therapeutic approaches based on pathophysiology"],"prefix":"10.1016","volume":"333","author":[{"given":"Richard A.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2013.06.018_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuron.2008.10.006","article-title":"LRP4 serves as a coreceptor of agrin","volume":"60","author":"Zhang","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.jns.2013.06.018_bb0010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","article-title":"Autoimmune response to acetylcholine receptor","volume":"180","author":"Patrick","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.jns.2013.06.018_bb0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/CND.0b013e31821c5634","article-title":"Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response","volume":"13","author":"Mittal","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.jns.2013.06.018_bb0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jns.2013.06.018_bb0025","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Viegas","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jns.2013.06.018_bb0030","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2013.06.018_bb0035","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jns.2013.06.018_bb0040","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2013.06.018_bb0050","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1212\/01.wnl.0000183145.91579.74","article-title":"Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG","volume":"65","author":"Hatanaka","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0055","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0060","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","article-title":"Evidence report: the medical treatment of ocular myasthenia (an evidence-based review); report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"68","author":"Benatar","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0065","first-page":"CD006986","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","author":"Mehndiratta","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jns.2013.06.018_bb0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.20515","article-title":"Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody","volume":"34","author":"Ponga","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.06.018_bb0075","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.nmd.2005.08.007","article-title":"The early history of myasthenia gravis","volume":"15","author":"Hughes","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jns.2013.06.018_bb0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0733-8619(18)30094-X","article-title":"The history of myasthenia gravis","volume":"12","author":"Pascuzzi","year":"1994","journal-title":"Neurol Clin"},{"key":"10.1016\/j.jns.2013.06.018_bb0085","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2013.06.018_bb0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mus.22103","article-title":"The thymus in myasthenia gravis: site of \u201cinnate autoimmunity\u201d?","volume":"44","author":"Cavalcante","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.06.018_bb0095","first-page":"378","article-title":"Greatly increased autoantibody production in myasthenia gravis by thymocyte suspensions prepared with proteolytic enzymes","volume":"54","author":"Willcox","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jns.2013.06.018_bb0100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4049\/jimmunol.137.4.1221","article-title":"Antibodies to acetylcholine receptor and tetanus toxoid: in vitro synthesis by thymic lymphocytes","volume":"137","author":"Lisak","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.jns.2013.06.018_bb0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter; thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0110","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treating autoimmune neuromuscular transmission disorders","volume":"17","author":"Skele","year":"2010","journal-title":"Eur J Neurol"},{"issue":"8000","key":"10.1016\/j.jns.2013.06.018_bb0115","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","article-title":"Remission of myasthenia gravis following plasma exchange","volume":"2","author":"Pinching","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2013.06.018_bb0120","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM197711242972102","article-title":"Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis","volume":"297","author":"Dau","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2013.06.018_bb0125","first-page":"292","article-title":"Symposium on therapeutic controversies. Myasthenia gravis. Plasmapheresis in the treatment of myasthenia gravis","volume":"103","author":"Lisak","year":"1978","journal-title":"Trans Am Neurol Assoc"},{"key":"10.1016\/j.jns.2013.06.018_bb0130","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mus.23626","article-title":"Safety of plasma exchange therapy in patients with myasthenia gravis","volume":"47","author":"Ebadi","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.06.018_bb0135","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0140","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jns.2013.06.018_bb0145","first-page":"CD005224","article-title":"Immunosuppressive agents for myasthenia gravis","author":"Hart","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jns.2013.06.018_bb0150","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.410150615","article-title":"Azathioprine in the treatment of myasthenia gravis","volume":"15","author":"Witte","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2013.06.018_bb0155","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/jnnp.56.11.1157","article-title":"A randomized clinical trial comparing prednisolone and azathioprine in myasthenia gravis. Results of a second interim analysis","volume":"56","author":"Myasthenia Gravis Clinical Study Group","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2013.06.018_bb0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.10018","article-title":"Successful treatment of myasthenia gravis with tacrolimus","volume":"25","author":"Evoli","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.06.018_bb0170","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mus.10472","article-title":"Clinical study of FK506 in patients with myasthenia gravis","volume":"28","author":"Konishi","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.06.018_bb0175","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.06.018_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2013.06.018_bb0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ana.10449","article-title":"Rebooting the immune system in myasthenia gravis: taking risks for a cure?","volume":"53","author":"Lewis","year":"2003","journal-title":"Editorial Ann. Neurol."},{"key":"10.1016\/j.jns.2013.06.018_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06832.x","article-title":"Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future","volume":"1274","author":"Dalakas","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jns.2013.06.018_bb0200","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI21545","article-title":"Induction of myasthenia gravis by immunization against muscle-specific kinase","volume":"116","author":"Shigemoto","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jns.2013.06.018_bb0205","first-page":"259","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Novak","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jns.2013.06.018_bb0210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0215","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role of B-cell activating factor in the pathogenesis of autoimmune MG","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2013.06.018_bb0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.2012.06842.x","article-title":"The role of B cell-activating factor in autoimmune myasthenia gravis","volume":"1274","author":"Lisak","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jns.2013.06.018_bb0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ana.410190119","article-title":"Suppressor T cells in myasthenia gravis and antibodies to acetylcholine receptor","volume":"19","author":"Lisak","year":"1986","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2013.06.018_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2013.06.018_bb0235","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1056\/NEJM197412122912403","article-title":"The thymus in myasthenia gravis. Evidence for altered cell population","volume":"291","author":"Abdou","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2013.06.018_bb0240","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1212\/WNL.28.12.1298","article-title":"Thymic and peripheral blood T- and B-cell levels in myasthenia gravis","volume":"28","author":"Lisak","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.06.018_bb0250","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clim.2008.03.509","article-title":"Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis","volume":"128","author":"Sheng","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jns.2013.06.018_bb0255","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1196\/annals.1405.023","article-title":"Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis","volume":"1132","author":"Meriggioli","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jns.2013.06.018_bb0260","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/mus.23488","article-title":"Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells","volume":"46","author":"Rowin","year":"2012","journal-title":"Muscle Nerve"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13002803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13002803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T20:08:04Z","timestamp":1688414884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X13002803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":51,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0022510X13002803"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2013.06.018","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis: New therapeutic approaches based on pathophysiology","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2013.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}